Factors associated with adherence and persistence to bisphosphonate therapy in osteoporosis: a cross-sectional survey
Factors associated with adherence and persistence to bisphosphonate therapy in osteoporosis: a cross-sectional survey
OBJECTIVE: To determine the factors associated with adherence and persistence to bisphosphonate therapy in osteoporosis.
DESIGN: Cross-sectional survey.
SETTING: National survey in the UK.
PARTICIPANTS: Participants were recruited through the National Osteoporosis Society and advertisements in the press and on the radio and included 533 women over age 50 with osteoporosis who were currently taking or had taken bisphosphonate therapy within the previous 12 months.
MAIN OUTCOME MEASURES: Self-reported factors influencing adherence and persistence to bisphosphonate therapy in osteoporosis: fracture history, pain, practical difficulties taking medication (frequency of dosing, dealing with comedications, impact on daily routine), perceptions of therapy, and concerns about bisphosphonate therapy.
RESULTS: Adherence to bisphosphonate therapy was 48% and was associated with previous fracture [odds ratio (OR) 1.62, 95% confidence interval (CI) 1.14-3.02], concerns about medication (OR 1.49, 95% CI 1.01-2.20), and less dissatisfaction with medication (OR 0.65, 95% CI 0.44-0.97). Nonpersistence was associated with dissatisfaction with medication (hazard ratio (HR) 1.83, 95% CI 1.38-2.43), side effects (HR 3.69, 95% CI 2.74-4.97), and concerns about bisphosphonate therapy (HR 2.21, 95% CI 1.48-3.30). For both daily (HR 1.53, 95% CI 1.1-2.33) and weekly bisphosphonates (HR 1.90, 95% CI 1.17-3.07), practical difficulties taking bisphosphonate medication-in particular, too frequent dosing-were associated with nonpersistence.
CONCLUSIONS: Self-reported nonadherence to daily and weekly bisphosphonates is independent of the decision to stop taking treatment (nonpersistence). Nonpersistence is associated with side effects and other factors that could be modified in clinical practice through education, information, and concordant partnerships.
societies, education, women, pain, bone, therapy, osteoporosis
1638-1644
Carr, A.J.
8989b4b9-e986-4599-8595-f17ab2f0c960
Thompson, P.W.
86fcf2fd-085e-4c76-a9e8-bdcf90008128
Cooper, C.
e05f5612-b493-4273-9b71-9e0ce32bdad6
2006
Carr, A.J.
8989b4b9-e986-4599-8595-f17ab2f0c960
Thompson, P.W.
86fcf2fd-085e-4c76-a9e8-bdcf90008128
Cooper, C.
e05f5612-b493-4273-9b71-9e0ce32bdad6
Carr, A.J., Thompson, P.W. and Cooper, C.
(2006)
Factors associated with adherence and persistence to bisphosphonate therapy in osteoporosis: a cross-sectional survey.
Osteoporosis International, 17 (11), .
(doi:10.1007/s00198-006-0166-2).
Abstract
OBJECTIVE: To determine the factors associated with adherence and persistence to bisphosphonate therapy in osteoporosis.
DESIGN: Cross-sectional survey.
SETTING: National survey in the UK.
PARTICIPANTS: Participants were recruited through the National Osteoporosis Society and advertisements in the press and on the radio and included 533 women over age 50 with osteoporosis who were currently taking or had taken bisphosphonate therapy within the previous 12 months.
MAIN OUTCOME MEASURES: Self-reported factors influencing adherence and persistence to bisphosphonate therapy in osteoporosis: fracture history, pain, practical difficulties taking medication (frequency of dosing, dealing with comedications, impact on daily routine), perceptions of therapy, and concerns about bisphosphonate therapy.
RESULTS: Adherence to bisphosphonate therapy was 48% and was associated with previous fracture [odds ratio (OR) 1.62, 95% confidence interval (CI) 1.14-3.02], concerns about medication (OR 1.49, 95% CI 1.01-2.20), and less dissatisfaction with medication (OR 0.65, 95% CI 0.44-0.97). Nonpersistence was associated with dissatisfaction with medication (hazard ratio (HR) 1.83, 95% CI 1.38-2.43), side effects (HR 3.69, 95% CI 2.74-4.97), and concerns about bisphosphonate therapy (HR 2.21, 95% CI 1.48-3.30). For both daily (HR 1.53, 95% CI 1.1-2.33) and weekly bisphosphonates (HR 1.90, 95% CI 1.17-3.07), practical difficulties taking bisphosphonate medication-in particular, too frequent dosing-were associated with nonpersistence.
CONCLUSIONS: Self-reported nonadherence to daily and weekly bisphosphonates is independent of the decision to stop taking treatment (nonpersistence). Nonpersistence is associated with side effects and other factors that could be modified in clinical practice through education, information, and concordant partnerships.
This record has no associated files available for download.
More information
Published date: 2006
Keywords:
societies, education, women, pain, bone, therapy, osteoporosis
Identifiers
Local EPrints ID: 60975
URI: http://eprints.soton.ac.uk/id/eprint/60975
ISSN: 0937-941X
PURE UUID: 74cf4346-fcd9-404f-b33e-e047cf143526
Catalogue record
Date deposited: 09 Sep 2008
Last modified: 18 Mar 2024 02:44
Export record
Altmetrics
Contributors
Author:
A.J. Carr
Author:
P.W. Thompson
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
